Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Protalix BioTherapeutics ...

    AMEX: PLX · Real-Time Price · USD
    1.44
    0.01 (0.70%)
    At close: Jun 17, 2025, 12:38 PM

    Protalix BioTherapeutics Statistics

    Share Statistics

    Protalix BioTherapeutics has 79.61M shares outstanding. The number of shares has increased by 6.43% in one year.

    Shares Outstanding

    n/a
    		 79.61M

    Shares Change (YoY)

    n/a
    		 6.43%

    Shares Change (QoQ)

    n/a
    		 5.97%

    Owned by Institutions (%)

    n/a
    		 6.07%

    Shares Floating

    n/a
    		 73.81M

    Failed to Deliver (FTD) Shares

    n/a
    		 751

    FTD / Avg. Volume

    n/a
    		 0.08%

    Short Selling Information

    The latest short interest is 956.15K, so 1.2% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 956.15K

    Short % of Shares Out

    n/a
    		 1.2%

    Short % of Float

    n/a
    		 1.25%

    Short Ratio (days to cover)

    n/a
    		 1.16

    Valuation Ratios

    The PE ratio is 46.51 and the forward PE ratio is 2.29. Protalix BioTherapeutics's PEG ratio is -0.7.

    PE Ratio

    n/a
    		 46.51

    Forward PE

    n/a
    		 2.29

    PS Ratio

    n/a
    		 2.55

    Forward PS

    n/a
    		 0.7

    PB Ratio

    n/a
    		 3.16

    P/FCF Ratio

    n/a
    		 18.45

    PEG Ratio

    n/a
    		 -0.7
    Financial Ratio History

    Enterprise Valuation

    Protalix BioTherapeutics has an Enterprise Value (EV) of 122.12M.

    EV / Sales

    n/a
    		 2.29

    EV / EBITDA

    n/a
    		 18.73

    EV / EBIT

    n/a
    		 14.08

    EV / FCF

    n/a
    		 16.52

    Financial Position

    The company has a current ratio of 2.34, with a Debt / Equity ratio of 0.13.

    Current Ratio

    n/a
    		 2.34

    Quick Ratio

    n/a
    		 1.52

    Debt / Equity

    n/a
    		 0.13

    Debt / EBITDA

    n/a
    		 0.85

    Debt / FCF

    n/a
    		 0.75

    Interest Coverage

    n/a
    		 3.69

    Financial Efficiency

    Return on Equity is 6.79% and Return on Invested Capital is 5.61%.

    Return on Equity

    n/a
    		 6.79%

    Return on Assets

    n/a
    		 3.99%

    Return on Invested Capital

    n/a
    		 5.61%

    Revenue Per Employee

    n/a
    		 $250,699.53

    Profits Per Employee

    n/a
    		 $13,765.26

    Employee Count

    n/a
    		 213

    Asset Turnover

    n/a
    		 0.73

    Inventory Turnover

    n/a
    		 1.14

    Taxes

    Income Tax

    n/a
    		 1.22M

    Effective Tax Rate

    n/a
    		 29.42%

    Stock Price Statistics

    The stock price has increased by 28.83% in the last 52 weeks. The beta is -0.22, so Protalix BioTherapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.22

    52-Week Price Change

    n/a
    		 28.83%

    50-Day Moving Average

    n/a
    		 2.12

    200-Day Moving Average

    n/a
    		 1.86

    Relative Strength Index (RSI)

    n/a
    		 30.05

    Average Volume (20 Days)

    n/a
    		 930,446

    Income Statement

    In the last 12 months, Protalix BioTherapeutics had revenue of 53.4M and earned 2.93M in profits. Earnings per share was 0.04.

    Revenue

    n/a
    		 53.4M

    Gross Profit

    n/a
    		 29.08M

    Operating Income

    n/a
    		 3.92M

    Net Income

    n/a
    		 2.93M

    EBITDA

    n/a
    		 6.52M

    EBIT

    n/a
    		 5.22M

    Earnings Per Share (EPS)

    n/a
    		 0.04
    Full Income Statement

    Balance Sheet

    The company has 19.76M in cash and 5.53M in debt, giving a net cash position of 14.23M.

    Cash & Cash Equivalents

    n/a
    		 19.76M

    Total Debt

    n/a
    		 5.53M

    Net Cash

    n/a
    		 14.23M

    Retained Earnings

    n/a
    		 -378.39M

    Total Assets

    n/a
    		 73.89M

    Working Capital

    n/a
    		 36.19M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 8.67M and capital expenditures -1.28M, giving a free cash flow of 7.39M.

    Operating Cash Flow

    n/a
    		 8.67M

    Capital Expenditures

    n/a
    		 -1.28M

    Free Cash Flow

    n/a
    		 7.39M

    FCF Per Share

    n/a
    		 0.1
    Full Cash Flow Statement

    Margins

    Gross margin is 54.46%, with operating and profit margins of 7.34% and 5.49%.

    Gross Margin

    n/a
    		 54.46%

    Operating Margin

    n/a
    		 7.34%

    Pretax Margin

    n/a
    		 7.78%

    Profit Margin

    n/a
    		 5.49%

    EBITDA Margin

    n/a
    		 12.21%

    EBIT Margin

    n/a
    		 7.34%

    FCF Margin

    n/a
    		 13.84%

    Dividends & Yields

    PLX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 2.15%

    FCF Yield

    n/a
    		 5.42%
    Dividend Details

    Analyst Forecast

    The average price target for PLX is $15, which is 949% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $15

    Price Target Difference

    n/a
    		 949%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 0.74

    Graham Upside

    n/a
    		 -48.25%

    Stock Splits

    The last stock split was on Dec 20, 2019. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Dec 20, 2019

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -2.97

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist